Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.

Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.

We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the connection domain and Q509L in ribonuclease H (RNase H) domain of HIV-1 reverse transcriptase (RT) which, together with the thymidine analog mutations D67N, K70R and T215F, confer greater than 100-fold AZT resistance....

Full description

Bibliographic Details
Main Authors: Jessica H Brehm, Yanille Scott, Dianna L Koontz, Steven Perry, Scott Hammer, David Katzenstein, John W Mellors, Nicolas Sluis-Cremer, AIDS Clinical Trials Group Study 175 Protocol Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3283647?pdf=render

Internet

http://europepmc.org/articles/PMC3283647?pdf=render

Similar Items